Physician profile
Daniel Rosas
NPI 1073133625
$4,601.66
in general payments reported to CMS, 2019-2025
23 companies · $2,465 in 2025
The $2,465 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $477 · 2023: $285 · 2024: $1,374 · 2025: $2,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,942 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,941.92 |
| Education | $182.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $699.10 | 2024-2025 | Rybrevant, Erleada, Balversa |
| Celgene Corporation | $507.58 | 2024-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $412.94 | 2022-2025 | Imfinzi, Enhertu |
| Regeneron Healthcare Solutions, INC. | $358.42 | 2024-2025 | Libtayo |
| Pfizer INC. | $348.96 | 2023-2025 | |
| Janssen Biotech, INC. | $287.41 | 2025 | Rybrevant, Carvykti |
| Tempus Ai, INC | $236.41 | 2025 | Xt Cdx |
| Amgen INC. | $234.82 | 2022 | |
| Incyte Corporation | $228.35 | 2022-2025 | Niktimvo |
| Genzyme Corporation | $194.09 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $126.93 | 2025 | |
| Astellas Pharma US INC | $125.00 | 2025 | Padcev |
| Immunocore Limited | $124.99 | 2025 | Kimmtrak |
| Springworks Therapeutics, INC. | $122.55 | 2024 | Ogsiveo |
| Stemline Therapeutics INC. | $109.98 | 2025 | Orserdu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $107.52 | 2024 | |
| Jazz Pharmaceuticals INC. | $91.73 | 2024 | |
| Genentech USA, INC. | $87.82 | 2024 | |
| Recordati_rare_diseases_inc. | $59.70 | 2024 | Sylvant |
| Abbvie INC. | $50.18 | 2025 | |
| Caris Mpi, INC. | $46.17 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $25.24 | 2025 | Onivyde |
| Novocure INC. | $15.77 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rosas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.